Activation of mammalian target of rapamycin (mTOR) in triple negative feline mammary carcinomas

Lorella Maniscalco, Yolanda Millán, Selina Iussich, Mauro Denina, Raquel Sánchez-Céspedes, Francesca Gattino, Bartolomeo Biolatti, Nobuo Sasaki, Takayuki Nakagawa, Maria Flavia Di Renzo, Juana Martín de las Mulas, Raffaella De Maria

Research output: Contribution to journalArticlepeer-review


Background: Triple negative breast cancer (TNBC) in humans is defined by the absence of oestrogen receptor (ER), progesterone receptor (PR) and HER2 overexpression. Mammalian target of rapamycin (mTOR) is overexpressed in TNBC and it represents a potential target for the treatment of this aggressive tumour. Feline mammary carcinoma (FMC) is considered to be a model for hormone-independent human breast cancer. This study investigated mTOR and p-mTOR expression in FMC in relation to triple negative (TN) phenotype.Results: The expression of mTOR, p-mTOR, ERα, PR and HER2 was evaluated in 58 FMCs by immunohistochemistry and in six FMC cell lines by Western blot analysis. 53.5% of FMC analyzed were ER, PR, HER2 negative (TN-FMC) while 56.9% and 55.2% of cases expressed mTOR and p-mTOR respectively. In this study we found that m-TOR and p-mTOR were more frequently detected in TN-FMC and in HER2 negative samples.Conclusions: In this study, we demonstrate that there is also a FMC subset defined as TN FMC, which is characterised by a statistically significant association with m-TOR and p-mTOR expression as demonstrated in human breast cancer.

Original languageEnglish
Article number80
JournalBMC Veterinary Research
Publication statusPublished - Apr 15 2013

ASJC Scopus subject areas

  • veterinary(all)
  • Medicine(all)


Dive into the research topics of 'Activation of mammalian target of rapamycin (mTOR) in triple negative feline mammary carcinomas'. Together they form a unique fingerprint.

Cite this